Cargando…
EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer
SIMPLE SUMMARY: Malignant Head and neck squamous cell carcinomas occur frequently, and several treatment regimens are used to fight disease progression. While anti-Epidermal growth factor receptor (EGFR) antibody cetuximab is applied successfully in many cases, therapy resistance occurs after a shor...
Autores principales: | Cserepes, Mihály, Nelhűbel, Györgyi A., Meilinger-Dobra, Mónika, Herczeg, Adrienn, Türk, Dóra, Hegedűs, Zita, Svajda, Laura, Rásó, Erzsébet, Ladányi, Andrea, Csikó, Kristóf György, Kenessey, István, Szöőr, Árpád, Vereb, György, Remenár, Éva, Tóvári, József |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140151/ https://www.ncbi.nlm.nih.gov/pubmed/35626010 http://dx.doi.org/10.3390/cancers14102407 |
Ejemplares similares
-
EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas
por: Nelhűbel, Györgyi A., et al.
Publicado: (2021) -
CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells
por: Mezősi-Csaplár, Marianna, et al.
Publicado: (2023) -
Cell type-dependent HIF1 α-mediated effects of hypoxia on proliferation, migration and metastatic potential of human tumor cells
por: Tátrai, Enikő, et al.
Publicado: (2017) -
KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models
por: Kenessey, István, et al.
Publicado: (2016) -
In vitro, in vivo and microscopic analysis of tumor immunotherapy using combination of two antibodies against the same ErbB2 target
por: Toth, Gabor, et al.
Publicado: (2014)